Drug

Rifampin

Approved · FDA

ClassBacterial DNA-directed RNA polymerase inhibitorEmerging researchLate-stage developmentRising momentum

Also known as 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, IsonaRif, RFP, Rifamate+7 more

3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, IsonaRif, RFP, Rifamate, Rifampicina, Rifampicine, Rifampicinum, Rifater, Rimactane, Rifadin, Rifampicin.

RxNorm9384 ChEMBLCHEMBL374478 ATCJ04AB02UNIIVJT6J7R4TR

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection

Clinical trial2026-07-02Results expected Q1 2027 · ClinicalTrials.gov

Approval: RIFAMPIN (ANDA219918)

Regulatory2026-06-29FDA

A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Clinical trial2026-06-23Results expected Q4 2026 · ClinicalTrials.gov

Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene

Clinical trial2026-06-22Results expected Q4 2027 · ClinicalTrials.gov

A Phase 2C Trial of Stratified Patient-Centered Treatment Regimens for Active TB

Clinical trial2026-06-15Results expected Q2 2029 · ClinicalTrials.gov

A Phase 1 Study to Evaluate the C-QTc Interval of QLC5508, Compare the Pharmacokinetics of Two Different Formulations, and Assess Drug-Drug Interaction Potential in Participants With Advanced Solid Tumors

Clinical trial2026-06-02Results expected Q4 2026 · ClinicalTrials.gov

A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis: Improved Management With Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)

Clinical trial2026-06-02Results expected Q2 2028 · ClinicalTrials.gov

A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of MDR-001 and the Effect of Itraconazole on the Pharmacokinetics of MDR-001 in Healthy Adult Study Participants

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB

Clinical trial2026-05-31Suspended · ClinicalTrials.gov

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

Research2024-03-28BMJ global health

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Research2006-03-30American journal of respiratory and critical care medicine

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Research2005-09-01American journal of respiratory and critical care medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Rifampin

Aliases & brands

3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SVIsonaRifRFPRifamateRifampicinaRifampicineRifampicinumRifaterRimactaneRifadinRifampicin

RxNorm CUI

9384

ChEMBL ID

CHEMBL374478

ATC codes

J04AB02

UNII

VJT6J7R4TR

Primary mechanism

Bacterial DNA-directed RNA polymerase inhibitor

Regulatory jurisdictions

fda

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

DNA-directed RNA polymerase subunit beta

rpoB · P0A8V2

INHIBITORBacterial DNA-directed RNA polymerase inhibitor

DNA-directed RNA polymerase subunit alpha

rpoA · P0A7Z4

INHIBITORBacterial DNA-directed RNA polymerase inhibitor

DNA-directed RNA polymerase subunit beta'

rpoC · P0A8T7

INHIBITORBacterial DNA-directed RNA polymerase inhibitor

DNA-directed RNA polymerase subunit omega

rpoZ · P0A800

INHIBITORBacterial DNA-directed RNA polymerase inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2026-06-29

Latest approval

2026-06-29

Authorities

FDA

Total events

fdaU.S. Food and Drug Administration· 1 event

2026-06-29Approval

Approval: RIFAMPIN (ANDA219918)

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

194 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

194

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

140

Completed

Discontinued

PHASE DISTRIBUTIONn = 194

Early Phase 11Phase 1118Phase 1 / 21Phase 228Phase 2 / 33Phase 320Phase 412Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

RecruitingPH IVBin Caon=1882028

Short-term Bactericidal Effect of Contezolid in Mycobacterium Avium Complex Pulmonary Disease

RecruitingPH IVBin Caon=1882027

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

CompletedPH IVHerlev and Gentofte Hospitaln=322023

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

WithdrawnPH IVJohns Hopkins University2021

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2

CompletedPH IVInstituto Nacional de Salud Publica, Mexicon=3962019

Recent completions

Trials that read out recently, adding to the completed evidence base.

Evaluation of Drug-Drug Interactions Between CS0159 Tablets and Rifampicin/Itraconazole and the Effect of a High-Fat Meal on the Pharmacokinetic Characteristics of CS0159 Tablets in Healthy Adult Participants

CompletedPH ICascade Pharmaceuticals, Incn=322026

A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

CompletedPH II/IIIJanssen Pharmaceutical K.K.n=1292025

A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Subjects

CompletedPH IGenentech, Inc.n=182025

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours

CompletedPH IBoehringer Ingelheimn=332025

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.

CompletedPH IIMcGill University Health Centre/Research Institute of the McGill University Health Centren=1,3682024

This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral Dose

CompletedPH ITYK Medicines, Incn=482024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20052024

Most influential

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

American journal of respiratory and critical care medicine · 2006 · 60 cites

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

American journal of respiratory and critical care medicine · 2005 · 43 cites

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

BMJ global health · 2024 · 4 cites

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ethionamide

Studied across the same disease area as Rifampin in the shared literature.

1 shared disease1 shared paper

Isoniazid

Studied across the same disease area as Rifampin in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.